The catalytic domain of CD13
faces the exterior of the plasma membrane and is anchored by a transmembrane-spanning domain, which is composed of N-terminal residues 9-32 (2).
The flow cytometric pattern of CD34, CD15 and CD13
expression in acute myeloblastic leukemia (AML) is highly characteristic of the presence of PML-RAR[alpha] gene rearrangements.
Coexpression of other markers included CD4, CD13
, CD33, CD34 (weak), CD56, and CD71 (data not shown).
Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD1 0, CD34, CD13
, and CD38 expresssion.
The results of a previous study involving an inhibition assay with specific monoclonal anti-CD13
antibodies [3, 5] demonstrated that aminopeptidase activity in sera from healthy individuals and patients with hepatobiliary disorders is predominantly attributable to CD13
In addition to immunophenotypic features noted above in immunohistochemistry, the neoplastic cells are typically negative for surface CD3, surface T-cell receptor (TCR), CD19, CD22, and CD13
by flow cytometric analysis.
CD3 PE (Coulter PN IM1282), CD7 FITC (Coulter PN IM0585), CD10 FITC (Coulter PN IM0471), CD13
FITC (Coulter PN IM0778), CD14 FITC (Coulter PN IM0650), CD19 FITC (Coulter PN IM1284), CD20 FITC (Coulter PN IM1455), CD33 FITC (Coulter PN IM1179), CD45 FITC (Coulter PN IM0782) and MPO FITC (Coulter PN IM1874) monoclonal antibodies were used for the diagnosis of ALL.
Typically, aberrant antigen profiles in neoplastic plasma cells include expression of CD28, CD56, CD20, CD117 (less commonly CD13
, CD33, CD44, or CD49d), diminished CD27, diminished CD38, and the complete absence of CD19 and/or CD45.
On flow cytometric immunophenotyping, the blasts were positive for CD34, CD45, CD10, CD19, and CD22 and negative for CD3, CD5, CD7 CD13
, CD33, CD14, CD42a, CD61, and glycophorin A.
Contract notice: Framework agreement for the purchase of event communication media, ceremonial items, flags and pavilions for the purposes of the CD13
Furthermore, lymphoblastic lymphoma/leukemia can express myeloid-associated antigens, such as CD13
Ninety-two percent of the blasts were CD7 and CD5-positive and CD13
, CD33, CD10, CD19, CD20, CD22, CD14 and HLA-DR-negative.